Kazia Therapeutics (KZIA) Consolidated Net Income (2009 - 2017)

Kazia Therapeutics' Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$8.2 million for Q2 2017.

• Quarterly Consolidated Net Income rose 10.04% year-over-year to -$8.2 million in Q2 2017, while the trailing twelve-month figure through Dec 2025 was $0.0 (changed 0.0% YoY) and the FY2025 annual result came in at -$13.3 million, up 24.13% from the prior year.
• Consolidated Net Income was -$8.2 million for Q2 2017 at Kazia Therapeutics, up from -$9.1 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$1.4 million in Q4 2013 and bottomed at -$9.1 million in Q2 2016.
• A 5-year average of -$6.6 million and a median of -$7.3 million in 2014 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2014 — Consolidated Net Income slumped 362.78% — and 2015, when it climbed 18.79%.
• Kazia Therapeutics' Consolidated Net Income stood at -$1.4 million in 2013, then tumbled by 362.78% to -$6.5 million in 2014, then increased by 18.79% to -$5.3 million in 2015, then sank by 72.49% to -$9.1 million in 2016, then increased by 9.97% to -$8.2 million in 2017.
• Business Quant data shows KZIA's Consolidated Net Income at -$8.2 million in Q2 2017, -$9.1 million in Q4 2016, and -$9.1 million in Q2 2016.